After BTIG and JMP Securities gave CTI BioPharma (NASDAQ: CTIC) a Buy rating last month, the company received another Buy, this time from Brookline Capital Markets. Analyst Leah R. Cann maintained a Buy rating on CTI BioPharma yesterday and set a price target of $12.00. The company’s shares closed last Thursday at $4.52.
According to TipRanks.com, Cann is a 3-star analyst with an average return of 1.3% and a 43.4% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.
CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $8.18, a 79.4% upside from current levels. In a report issued on April 13, BTIG also maintained a Buy rating on the stock with a $10.00 price target.
The company has a one-year high of $5.25 and a one-year low of $1.43. Currently, CTI BioPharma has an average volume of 5.25M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Read More on CTIC:
- Oppenheimer Says These 2 Stocks Could Surge Over 50% From Current Levels
- Mizuho Securities Issues a Buy Rating on Arcus Biosciences (RCUS)
- Mizuho Securities Sticks to Its Buy Rating for Magenta Therapeutics (MGTA)
- Wedbush Maintains a Hold Rating on US Bancorp (USB)
- Charter Equity Keeps a Hold Rating on Telefonaktiebolaget LM Ericsson (ERIC)